ResearcherNational Institutes of HealthActive in the last 2 years
Ondřej Uher
Matched on ORCID iD 0000-0003-3978-9822; OpenAlex author ID A5019977110. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment. Co-author DOI 10.1080/15384047.2026.2683273↗
- The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreati… Co-author DOI 10.1016/j.intimp.2023.110150↗
- Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Co-author DOI 10.1007/s00262-021-02920-9↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jan Ženka · 3 shared papers, 2021–2026 · strength 0.54
- Paper Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence … DOI 10.1080/15384047.2026.2683273↗
- Paper The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for … DOI 10.1016/j.intimp.2023.110150↗
- Paper Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding the… DOI 10.1007/s00262-021-02920-9↗
- Andrea Frejlachova · 3 shared papers, 2021–2026 · strength 0.54
- Paper Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence … DOI 10.1080/15384047.2026.2683273↗
- Paper The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for … DOI 10.1016/j.intimp.2023.110150↗
- Paper Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding the… DOI 10.1007/s00262-021-02920-9↗
- David Větvička · 1 shared paper, 2026 · strength 0.28
- Katerina Hadrava Vanova · 1 shared paper, 2026 · strength 0.28
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.